Plerixafor MM02: mobilization of peripheral blood stem cells in multiple myeloma undergoing autologous stem cell transplantation

Phase 2, open-label, single-arm trial of plerixafor in multiple myeloma (MM), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Number of CD34+ cells mobilized into peripheral blood, Percentage of patients collecting ≥ 6 x 10^6 CD34+ cells/kg in three or fewer apheresis procedures and 1 more. Started Mar 2012; status: completed.